ReviewMolecular biology reports2026
Advances in biomarkers for differential diagnosis of autoimmune and autoinflammatory inner ear disorders.
Review in Molecular biology reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Autoimmune inner ear disease (AIED) represents a rare yet potentially reversible cause of sensorineural hearing loss, characterized by immune-mediated damage to cochlear and vestibular structures. Unlike autoimmunity, which is driven by adaptive immune responses and autoantibodies, autoinflammation stems from innate immune system dysregulation, typically involving inflammasome hyperactivation. This review synthesizes recent advancements in biomarkers for the differential diagnosis of AIED, emphasizing their role in distinguishing it from conditions such as Meniere's disease (MD) and chronic otitis media (COM). Autoantibodies and cytokines, including anti-heat shock protein 70 (HSP70), interleukin-1β (IL-1β), tumor necrosis factor-α (TNF-α), interleukin-6 (IL-6), antiphospholipid antibodies, anti-type II collagen, selective immunoglobulin A deficiency (sIgAD), and anti-cochlin antibodies, have a significant role in diagnostic sensitivity, specificity, and correlations with treatment responsiveness. Additionally, we discuss the utility of magnetic resonance imaging (MRI) in identifying inner ear enhancements and propose diagnostic algorithms to facilitate early detection. By integrating serological, immunological, and radiological insights, this work underscores the potential of these biomarkers to guide personalized therapeutic strategies, including corticosteroids and biologics, while addressing diagnostic challenges and the need for standardized criteria. Ultimately, enhanced biomarker utilization may improve outcomes in AIED by enabling timely intervention and reducing misdiagnosis.
Indexed as
Identifiers
42340468What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.